The potential of 1018 ISS adjuvant in hepatitis B vaccines

References

• World Health Organization. Hepatitis B: Fact Sheet No. 204. Vaccine 2012; 30:3061 - 7; PMID: 22406109
   PubMed Web of Science ®Google Scholar
• Falade-Nwulia O, Seaberg EC, Rinaldo CR, Badri S, Witt M, Thio CL. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis 2012; 55:507 - 13; http://dx.doi.org/10.1093/cid/cis432; PMID: 22523269
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis B vaccines. Wkly Epidemiol Rec 2009; 84:405 - 19; PMID: 19817017
   PubMedGoogle Scholar
• Nassal M. Hepatitis B virus replication: novel roles for virus-host interactions. Intervirology 1999; 42:100 - 16; http://dx.doi.org/10.1159/000024970; PMID: 10516465
   PubMed Web of Science ®Google Scholar
• Hollinger FB, Liang TJ. Hepatitis B virus. 2001; 2971 - 3036
   Google Scholar
• Pan J, Lian Z, Wallett S, Feitelson MA. The hepatitis B x antigen effector, URG7, blocks tumour necrosis factor alpha-mediated apoptosis by activation of phosphoinositol 3-kinase and beta-catenin. J Gen Virol 2007; 88:3275 - 85; http://dx.doi.org/10.1099/vir.0.83214-0; PMID: 18024896
   PubMed Web of Science ®Google Scholar
• Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997; 99:1472 - 7; http://dx.doi.org/10.1172/JCI119308; PMID: 9119989
   PubMed Web of Science ®Google Scholar
• Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004; 101:6669 - 74; http://dx.doi.org/10.1073/pnas.0401771101; PMID: 15100412
   PubMed Web of Science ®Google Scholar
• Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5:215 - 29; http://dx.doi.org/10.1038/nri1573; PMID: 15738952
   PubMed Web of Science ®Google Scholar
• Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 2005; 79:9369 - 80; http://dx.doi.org/10.1128/JVI.79.15.9369-9380.2005; PMID: 16014900
   PubMed Web of Science ®Google Scholar
• Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000; 32:1117 - 24; http://dx.doi.org/10.1053/jhep.2000.19324; PMID: 11050064
   PubMed Web of Science ®Google Scholar
• Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98:1185 - 94; http://dx.doi.org/10.1172/JCI118902; PMID: 8787682
   PubMed Web of Science ®Google Scholar
• Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77:68 - 76; http://dx.doi.org/10.1128/JVI.77.1.68-76.2003; PMID: 12477811
   PubMed Web of Science ®Google Scholar
• Baumert TF, Thimme R, von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13:82 - 90; PMID: 17206757
   PubMed Web of Science ®Google Scholar
• Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981; 1:377 - 85; http://dx.doi.org/10.1002/hep.1840010502; PMID: 7030902
   PubMed Web of Science ®Google Scholar
• Crossley KB, Gerding DN, Petzel RA. Acceptance of hepatitis B vaccine by hospital personnel. Infect Control 1985; 6:147 - 9; PMID: 3157659
   PubMedGoogle Scholar
• Huang K, Lin S. Nationwide vaccination: a success story in Taiwan. Vaccine 2000; 18:Suppl 1 S35 - 8; http://dx.doi.org/10.1016/S0264-410X(99)00460-0; PMID: 10683542
   PubMed Web of Science ®Google Scholar
• Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2006; CD004790; PMID: 16625613
   PubMedGoogle Scholar
• Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 135:796 - 800; http://dx.doi.org/10.7326/0003-4819-135-9-200111060-00009; PMID: 11694104
   PubMed Web of Science ®Google Scholar
• Seeff LB, Wright EC, Zimmerman HJ, Alter HJ, Dietz AA, Felsher BF, et al. Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med 1978; 88:285 - 93; http://dx.doi.org/10.7326/0003-4819-88-3-285; PMID: 343678
   PubMed Web of Science ®Google Scholar
• Francis DP, Hadler SC, Thompson SE, Maynard JE, Ostrow DG, Altman N, et al. The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men. Ann Intern Med 1982; 97:362 - 6; http://dx.doi.org/10.7326/0003-4819-97-3-362; PMID: 6810736
   PubMed Web of Science ®Google Scholar
• Bialek SR, Bower WA, Novak R, Helgenberger L, Auerbach SB, Williams IT, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008; 27:881 - 5; http://dx.doi.org/10.1097/INF.0b013e31817702ba; PMID: 18756185
   PubMed Web of Science ®Google Scholar
• Floreani A, Baldo V, Cristofoletti M, Renzulli G, Valeri A, Zanetti C, et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 2004; 22:607 - 10; http://dx.doi.org/10.1016/j.vaccine.2003.09.001; PMID: 14741151
   PubMed Web of Science ®Google Scholar
• Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective?. J Infect Dis 1999; 179:489 - 92; http://dx.doi.org/10.1086/314578; PMID: 9878036
   PubMed Web of Science ®Google Scholar
• Banatvala JE, Van Damme P. Hepatitis B vaccine -- do we need boosters?. J Viral Hepat 2003; 10:1 - 6; http://dx.doi.org/10.1046/j.1365-2893.2003.00400.x; PMID: 12558904
   PubMed Web of Science ®Google Scholar
• Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004; 2:941 - 5; http://dx.doi.org/10.1016/S1542-3565(04)00384-2; PMID: 15476159
   PubMed Web of Science ®Google Scholar
• André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989; 87:3A 14S - 20S; http://dx.doi.org/10.1016/0002-9343(89)90525-1; PMID: 2528292
   PubMed Web of Science ®Google Scholar
• Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:RR-16 1 - 33, quiz CE1-4; PMID: 17159833
   PubMedGoogle Scholar
• Cassidy WM, Watson B, Ioli VA, Williams K, Bird S, West DJ. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics 2001; 107:626 - 31; http://dx.doi.org/10.1542/peds.107.4.626; PMID: 11335734
   PubMed Web of Science ®Google Scholar
• Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman R, Sztein MB. Vaccination in the elderly: an immunological perspective. Trends Immunol 2009; 30:351 - 9; http://dx.doi.org/10.1016/j.it.2009.05.002; PMID: 19540808
   PubMed Web of Science ®Google Scholar
• Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003; 63:1021 - 51; http://dx.doi.org/10.2165/00003495-200363100-00006; PMID: 12699402
   PubMed Web of Science ®Google Scholar
• Harris A, Yong K, Kermode M. An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness. Aust N Z J Public Health 2001; 25:222 - 9; http://dx.doi.org/10.1111/j.1467-842X.2001.tb00566.x; PMID: 11494989
   PubMed Web of Science ®Google Scholar
• Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995; 274:1201 - 8; http://dx.doi.org/10.1001/jama.1995.03530150025029; PMID: 7563509
   PubMed Web of Science ®Google Scholar
• De Wilde M, Cabezon T, Harford N, Rutgers T, Simoen E, Van Wijnendaele F. Production in yeast of hepatitis B surface antigen by R-DNA technology. Dev Biol Stand 1985; 59:99 - 107; PMID: 4007280
   PubMedGoogle Scholar
• Hauser P, Voet P, Simoen E, Thomas HC, Pêtre J, De Wilde M, et al. Immunological properties of recombinant HBsAg produced in yeast. Postgrad Med J 1987; 63:Suppl 2 83 - 91; PMID: 2446304
   PubMed Web of Science ®Google Scholar
• Pêtre J, Van Wijnendaele F, De Neys B, Conrath K, Van Opstal O, Hauser P, et al. Development of a hepatitis B vaccine from transformed yeast cells. Postgrad Med J 1987; 63:Suppl 2 73 - 81; PMID: 3317362
   PubMedGoogle Scholar
• Marangi AL, Giordano R, Montanaro A, De Padova F, Schiavone MG, Dongiovanni G, et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis 1994; 23:537 - 42; PMID: 8154489
   PubMed Web of Science ®Google Scholar
• Marangi AL, Giordano R, Montanaro A, De Padova F, Schiavone MG, Fedele AR, et al. A successful two-step integrated protocol of anti-HBV vaccination in chronic uremia. Nephron 1992; 61:331 - 2; http://dx.doi.org/10.1159/000186928; PMID: 1386907
   PubMedGoogle Scholar
• André FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990; 8:Suppl S74 - 8, discussion S79-80; http://dx.doi.org/10.1016/0264-410X(90)90222-8; PMID: 2139288
   PubMed Web of Science ®Google Scholar
• Wiedermann G, Scheiner O, Ambrosch F, Kraft D, Kollaritsch H, Kremsner P, et al. Lack of induction of IgE and IgG antibodies to yeast in humans immunized with recombinant hepatitis B vaccines. Int Arch Allergy Appl Immunol 1988; 85:130 - 2; http://dx.doi.org/10.1159/000234489; PMID: 2962947
   PubMedGoogle Scholar
• Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN, Nair PV, et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987; 257:2612 - 6; http://dx.doi.org/10.1001/jama.1987.03390190090026; PMID: 2952812
   PubMed Web of Science ®Google Scholar
• Lemon SM, Weber DJ. Immunogenicity of plasma-derived hepatitis B vaccine: relationship to site of injection and obesity. J Gen Intern Med 1986; 1:199 - 201; http://dx.doi.org/10.1007/BF02602339; PMID: 2945916
   PubMed Web of Science ®Google Scholar
• de Lalla F, Rinaldi E, Santoro D, Pravettoni G. Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study. Eur J Epidemiol 1988; 4:256 - 8; http://dx.doi.org/10.1007/BF00144763; PMID: 2969825
   PubMed Web of Science ®Google Scholar
• Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996; 272:54 - 60; http://dx.doi.org/10.1126/science.272.5258.54; PMID: 8600537
   PubMed Web of Science ®Google Scholar
• Marsano LS, West DJ, Chan I, Hesley TM, Cox J, Hackworth V, et al. A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. Vaccine 1998; 16:624 - 9; http://dx.doi.org/10.1016/S0264-410X(97)00233-8; PMID: 9569474
   PubMed Web of Science ®Google Scholar
• Venters C, Graham W, Cassidy W. Recombivax-HB: perspectives past, present and future. Expert Rev Vaccines 2004; 3:119 - 29; http://dx.doi.org/10.1586/14760584.3.2.119; PMID: 15056038
   PubMedGoogle Scholar
• Leroux-Roels G, Abraham B, Fourneau M, De Clercq N, Safary A. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents. Vaccine 2000; 19:937 - 42; http://dx.doi.org/10.1016/S0264-410X(00)00217-6; PMID: 11115719
   PubMed Web of Science ®Google Scholar
• Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007; 6:133 - 40; http://dx.doi.org/10.1586/14760584.6.2.133; PMID: 17408363
   PubMed Web of Science ®Google Scholar
• Tong NK, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005; 68:2298 - 303; http://dx.doi.org/10.1111/j.1523-1755.2005.00689.x; PMID: 16221232
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Wiedermann G, Kundi M, Leroux-Roels G, Desombere I, Garcon N, et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 2000; 18:2095 - 101; http://dx.doi.org/10.1016/S0264-410X(99)00566-6; PMID: 10715523
   PubMed Web of Science ®Google Scholar
• Boland G, Beran J, Lievens M, Sasadeusz J, Dentico P, Nothdurft H, et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 2004; 23:316 - 20; http://dx.doi.org/10.1016/j.vaccine.2004.06.006; PMID: 15530674
   PubMed Web of Science ®Google Scholar
• Levie K, Gjorup I, Skinhøj P, Stoffel M. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand J Infect Dis 2002; 34:610 - 4; http://dx.doi.org/10.1080/00365540110080881; PMID: 12238579
   PubMed Web of Science ®Google Scholar
• Rebedea I, Diaconescu IG, Bach D, Bartelsen O, Arndtz N. Comparison of thiomersal-free and thiomersal-containing formulations of a recombinant hepatitis B vaccine (Hepavax-Gene) in healthy adults. Vaccine 2006; 24:5320 - 6; http://dx.doi.org/10.1016/j.vaccine.2006.04.018; PMID: 16707195
   PubMed Web of Science ®Google Scholar
• Hieu NT, Kim KH, Janowicz Z, Timmermans I. Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years. Vaccine 2002; 20:1803 - 8; http://dx.doi.org/10.1016/S0264-410X(01)00518-7; PMID: 11906768
   PubMed Web of Science ®Google Scholar
• Raz R, Koren R, Bass D. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults. Isr Med Assoc J 2001; 3:328 - 32; PMID: 11411195
   PubMed Web of Science ®Google Scholar
• Shapira MY, Zeira E, Adler R, Shouval D. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol 2001; 34:123 - 7; http://dx.doi.org/10.1016/S0168-8278(00)00082-9; PMID: 11211888
   PubMed Web of Science ®Google Scholar
• Yerushalmi B, Raz R, Blondheim O, Shumov E, Koren R, Dagan R. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates. Pediatr Infect Dis J 1997; 16:587 - 92; http://dx.doi.org/10.1097/00006454-199706000-00009; PMID: 9194109
   PubMed Web of Science ®Google Scholar
• De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 2008; 38:2068 - 71; http://dx.doi.org/10.1002/eji.200838648; PMID: 18651701
   PubMed Web of Science ®Google Scholar
• Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008; 105:10501 - 6; http://dx.doi.org/10.1073/pnas.0804699105; PMID: 18650390
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82:488 - 96; http://dx.doi.org/10.1111/j.0818-9641.2004.01272.x; PMID: 15479434
   PubMed Web of Science ®Google Scholar
• Halperin SA, McNeil S, Langley JM, Smith B, MacKinnon-Cameron D, McCall-Sani R, et al. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults. Vaccine 2012; 30:5445 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.05.074; PMID: 22704926
   PubMed Web of Science ®Google Scholar
• Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine 2012; 30:2556 - 63; http://dx.doi.org/10.1016/j.vaccine.2012.01.087; PMID: 22326642
   PubMed Web of Science ®Google Scholar
• Janowicz ZA, Melber K, Merckelbach A, Jacobs E, Harford N, Comberbach M, et al. Simultaneous expression of the S and L surface antigens of hepatitis B, and formation of mixed particles in the methylotrophic yeast, Hansenula polymorpha. Yeast 1991; 7:431 - 43; http://dx.doi.org/10.1002/yea.320070502; PMID: 1897310
   PubMed Web of Science ®Google Scholar
• Pisetsky DS. Immune activation by bacterial DNA: a new genetic code. Immunity 1996; 5:303 - 10; http://dx.doi.org/10.1016/S1074-7613(00)80256-3; PMID: 8885863
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol 1992; 148:4072 - 6; PMID: 1376349
   PubMed Web of Science ®Google Scholar
• Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A 1999; 96:9305 - 10; http://dx.doi.org/10.1073/pnas.96.16.9305; PMID: 10430938
   PubMed Web of Science ®Google Scholar
• Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A 1996; 93:2879 - 83; http://dx.doi.org/10.1073/pnas.93.7.2879; PMID: 8610135
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546 - 9; http://dx.doi.org/10.1038/374546a0; PMID: 7700380
   PubMed Web of Science ®Google Scholar
• Krieg AM, Matson S, Fisher E. Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev 1996; 6:133 - 9; http://dx.doi.org/10.1089/oli.1.1996.6.133; PMID: 8843328
   PubMedGoogle Scholar
• Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE. Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest 1996; 98:1119 - 29; http://dx.doi.org/10.1172/JCI118894; PMID: 8787674
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33:492 - 503; http://dx.doi.org/10.1016/j.immuni.2010.10.002; PMID: 21029960
   PubMed Web of Science ®Google Scholar
• Van Nest G. An immunostimulatory oligonucleotide (ISS ODN) enhances immune responses to HBV vaccine in a variety of animal species including non-human primates. In 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA. USA 1999;
   Google Scholar
• Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin Biol Ther 2007; 7:1731 - 7; http://dx.doi.org/10.1517/14712598.7.11.1731; PMID: 17961095
   PubMed Web of Science ®Google Scholar
• Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003; 21:2461 - 7; http://dx.doi.org/10.1016/S0264-410X(03)00045-8; PMID: 12744879
   PubMed Web of Science ®Google Scholar
• Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006; 24:20 - 6; http://dx.doi.org/10.1016/j.vaccine.2005.08.095; PMID: 16198027
   PubMed Web of Science ®Google Scholar
• Sablan BP, Kim DJ, Barzaga NG, Chow WC, Cho M, Ahn SH, et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012; 30:2689 - 96; http://dx.doi.org/10.1016/j.vaccine.2012.02.001; PMID: 22342916
   PubMed Web of Science ®Google Scholar
• McNeil S, Halperin SA, Hart R, Miller MA, Lipman M, Soroka SD, et al. Safety and immunogenicity of a novel hepatitis B vaccine adjuvanted with immunostimulatory sequence (ISS) in renal predialysis and dialysis patients. In National Kidney Foundation Spring Meetings. Orlando, FL, USA 2010;
   Google Scholar
• Briefing Document FDA. HEPLISAV (Hepatitis B Vaccine Recombinant and 1018 ISS Adjuvant). Vaccines and Related Biological Products Advisory Committee Meeting 2012
   Google Scholar
• Martin-Orozco E, Kobayashi H, Van Uden J, Nguyen MD, Kornbluth RS, Raz E. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol 1999; 11:1111 - 8; http://dx.doi.org/10.1093/intimm/11.7.1111; PMID: 10383944
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004; 24:693 - 701; http://dx.doi.org/10.1007/s10875-004-6244-3; PMID: 15622454
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005; 19:1473 - 9; http://dx.doi.org/10.1097/01.aids.0000183514.37513.d2; PMID: 16135900
   PubMed Web of Science ®Google Scholar
• Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325 - 9; http://dx.doi.org/10.1016/0140-6736(90)91874-A; PMID: 1697396
   PubMed Web of Science ®Google Scholar
• Waters JA, Kennedy M, Voet P, Hauser P, Petre J, Carman W, et al. Loss of the common “A” determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992; 90:2543 - 7; http://dx.doi.org/10.1172/JCI116148; PMID: 1281839
   PubMed Web of Science ®Google Scholar
• Kalinina T, Iwanski A, Will H, Sterneck M. Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R. Hepatology 2003; 38:1274 - 81; http://dx.doi.org/10.1053/jhep.2003.50484; PMID: 14578867
   PubMed Web of Science ®Google Scholar
• Ogata N, Cote PJ, Zanetti AR, Miller RH, Shapiro M, Gerin J, et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology 1999; 30:779 - 86; http://dx.doi.org/10.1002/hep.510300309; PMID: 10462386
   PubMed Web of Science ®Google Scholar
• Bauer T, Weinberger K, Jilg W. Variants of two major T cell epitopes within the hepatitis B surface antigen are not recognized by specific T helper cells of vaccinated individuals. Hepatology 2002; 35:455 - 65; http://dx.doi.org/10.1053/jhep.2002.30903; PMID: 11826423
   PubMed Web of Science ®Google Scholar